Program
Anti-EGFR/Anti-c-Met Bispecific Antibody-drug Conjugate VBC101
Its studies are led by VelaVigo Cayman.
Furthest: phase 2, since Aug 15, 20251 company-led study, 1 open or runningNext primary completion: Jul 1, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| VelaVigo Cayman | 11 open or running | phase 2since Aug 15, 2025 | Aug 15, 2025 | Jul 1, 2027phase 2 · NCT07136779 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 15, 2025First study: phase 2 study in Participants With Advanced Solid Tumor MalignanciesFirst studyNCT07136779 · 310 planned · United States
Ahead
- Jul 1, 2027Primary completion: phase 2 study in Participants With Advanced Solid Tumor MalignanciesNCT07136779
TargetBeta
“A nanobody-based antibody-drug conjugate (ADC) composed of a low-affinity antibody fragment targeting epidermal growth factor receptor (EGFR) coupled with a high-affinity antibody fragment targeting hepatocyte growth factor receptor (HGFR; c-Met) ”NCIt, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| amivantamabrule | Johnson & Johnson | phase 3 | 16 |
| bafisontamabrule | shanghai-epimab-biotherapeutics-co-ltd | phase 3 | 5 |
| HS-20117 | Hansoh Pharmaceutical Group | phase 3 | 3 |
| pamvatamigrule | Betta Pharmaceuticals | phase 2 | 5 |
| TQB2922 | Sino Biopharmaceutical | phase 2 | 5 |
| TQB6411 | Sino Biopharmaceutical | phase 2 | 3 |
| Anti-c-Met/EGFR/VEGF Trispecific Antibody TAVO412rule | tavotek-biotherapeutics | phase 1 | 2 |
| HS-20122 | Hansoh Pharmaceutical Group | phase 1 | 2 |
| Anti-EGFR/c-Met/c-Met-Topoisomerase-1 Inhibitor Trispecific Antibody-drug Conjugate BG-C0902rule | BeOne Medicines | phase 1 | 1 |
| Anti-EGFR/c-Met-CPT-113 Antibody-drug Conjugate JNJ-95437446 | Johnson & Johnson | phase 1 | 1 |
| HLX48 | Fosun Pharma | phase 1 | 1 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07136779Participants With Advanced Solid Tumor Malignancies · United States | 2 | Recruiting | Jul 1, 2027 | 310 |
How it is read
Names in the registry
- “VBC101”, 1 entry
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.